IRWD Q4 2023 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$118M+9.7% YoY

Gross Profit

$118M100.0% margin

Operating Income

$38M32.0% margin

Net Income

-$1M-0.9% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$36M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$471M

Total Liabilities

$817M

Stockholders' Equity

-$346M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$107M	+9.7%
Gross Profit	$118M	$107M	+10.0%
Operating Income	$38M	$68M	-45.0%
Net Income	-$1M	$49M	-102.2%

Geographic Segments

North America

$432M100%